Covariates and outcomes | n | Value | Liver | Lung | p-value |
---|---|---|---|---|---|
Sex | 388 | ||||
Male | 271 | 69.8 | 72.2 | 65.4 | 0.200 |
Female | 117 | 30.2 | 27.8 | 34.6 | |
Age [years] | 388 | 66 (24–93) | 66 (24–93) | 70 (38–36) | 0.00399 |
Baseline Karnofsky index | 283 | ||||
< 90 | 97 | 34.2 | 30.6 | 40.9 | 0.125 |
≥90 | 186 | 65.7 | 69.4 | 59.1 | |
Solitary metastasis | 304 | ||||
Yes | 110 | 36.2 | 33.2 | 40.7 | 0.184 |
No | 194 | 63.8 | 66.8 | 59.3 | |
Number of treated metastases | 388 | ||||
1 | 321 | 82.7 | 89.4 | 69.9 | |
2 | 42 | 10.8 | 8.2 | 15.8 | |
3 | 13 | 3.4 | 1.6 | 6.8 | |
4 | 7 | 1.8 | 0.4 | 4.5 | |
5 | 2 | 0.5 | 0.4 | 0.7 | |
6 | 3 | 0.8 | 0 | 2.3 | |
Tumor site | 500 | ||||
Liver | 291 | 58.2 | |||
Lung | 209 | 41.8 | |||
Tumor volume [ccm] (gross tumor volume, GTV) | 342 | 9.20 (0.07–699) | 26.0 (0.8–699) | 3.1 (0.07–268) | < 0.0001 |
Chemotherapy prior to SBRT | 430 | ||||
Yes | 332 | 77.2 | 84.5 | 68.5 | < 0.0001 |
No | 98 | 22.8 | 15.5 | 31.5 | |
Dose calculation algorithm | 496 | ||||
Pencil beam | 199 | 40.1 | 56.4 | 17.7 | < 0.0001 |
Advanced | 297 | 59.9 | 43.6 | 82.3 | |
Motion management | 500 | ||||
Free breathing | 347 | 69.4 | 75.3 | 73.7 | 0.755 |
Advanced | 153 | 30.6 | 24.7 | 26.3 | |
BEDiso [Gy10] | 500 | 126.9 (37.5–309.4) | 124.8 (37.5–234.5) | 141.1 (39.4–309.4) | < 0.0001 |
Outcomes | 388 | ||||
Local failure and censored prior to death | 28 | 7.2 | 7.5 | 6.8 | < 0.0001 |
Local failure and death | 71 | 18.3 | 24.3 | 6.8 | |
Death without local failure | 133 | 34.3 | 36.5 | 30.0 | |
Censored prior to local failure or death | 156 | 40.2 | 31.8 | 56.4 |